Compassionate Use and Expanded Access programs in jurisdictions like the United States and Australia are vital in providing lifesaving or life-extending treatment options for patients with severe or life-threatening conditions. These pathways, such as the FDA’s Expanded Access program and Australia’s Special Access Scheme, grant patients access to investigational therapies that have not yet received regulatory approval. While their intent is altruistic, allowing individuals without other viable treatment options a final lifeline, these programs present significant challenges when they are utilised as substitutes for traditional clinical trials.
At the heart of the debate is the question of whether compassionate use schemes should merely complement clinical trials or whether they risk undermining the scientific rigor and ethical integrity that trials are designed to uphold. Compassionate use programs inherently lack the structured, controlled environment of clinical trials. Trials operate under strict protocols that define participant selection, dosing regimens, outcome measurements, and safety assessments. Conversely, compassionate use pathways often involve patients with advanced disease stages or complex comorbidities, introducing variables that can distort efficacy and safety evaluations. An excess number of adverse outcomes in a compassionate use group could compromise marketing approval after clinical studies are complete. Data collected under these circumstances is frequently inconsistent, non-reproducible, and unsuitable for inclusion in regulatory submissions.
This undermines the potential for compassionate use programs to contribute meaningfully to drug approval processes, delaying broader patient access to the therapy.
Regulatory agencies such as the FDA and TGA provide oversight for these programs, emphasizing safety and ethical considerations. However, this oversight often comes at the cost of regulatory complexity and delays. Sponsors must navigate substantial documentation requirements and provide comprehensive risk-benefit analyses. While this protects patients from undue harm, it also slows the initiation of compassionate use treatments. Moreover, adverse events occurring under compassionate use, even when unrelated to the investigational product, can negatively influence regulatory perceptions of a drug’s safety profile. This introduces a paradox: while aiming to accelerate access for individuals in urgent need, compassionate use can inadvertently hinder the product’s overall development and approval.
Beyond regulatory challenges, compassionate use programs can disrupt the ecosystem of clinical trials in several ways. Providing investigational drugs outside of clinical trials can disincentivize eligible patients from enrolling in well-controlled studies. This can delay recruitment efforts and may impede timely trial completion. Moreover, including compassionate use data in trial datasets risks skewing results, compromising the validity of trial outcomes. The fragmented approach of running parallel compassionate use programs and clinical trials also burdens sponsors operationally, straining supply chains and diverting resources from priority development activities.
Compassionate use pathways also raise ethical concerns. Patients and families often approach these programs with hope but may lack a full understanding of the experimental nature of the treatment. Sponsors and healthcare providers bear a significant ethical responsibility to ensure consent is genuinely informed, transparent and free of unrealistic expectations. Moreover, these programs frequently lack the infrastructure for rigorous monitoring and reporting of outcomes, which is a cornerstone of clinical trial design. This compromises not only the safety of individual patients but also the broader integrity of the development program.
Advocates for traditional clinical trials highlight the unmatched scientific rigor of randomized, controlled studies. These trials are designed to minimize bias, optimize dosing strategies, and provide statistically significant data on safety and efficacy. Such data is critical for regulatory approval, insurance reimbursement, and integration into clinical practice guidelines. While compassionate use programs are indispensable for providing immediate access to investigational therapies for individual patients, they do not replace the need for high-quality evidence generated through formal clinical trials. Without this evidence, even the most promising therapies risk languishing in regulatory limbo, inaccessible to the wider patient population. Probably no drug better illustrates the pitfalls of compassionate use and the resultant regulatory limbo than ganciclovir. Although compassionate use of ganciclovir was successful in many patients suffering from human cytomegalovirus (CMV) retinitis, the FDA rejected application for the approval of ganciclovir because of scarcity of data from clinical trials. It was also difficult to conduct placebo controlled clinical trial in such cases where compassionate use of ganciclovir is already showing benefit during compassionate use.
Furthermore, clinical trials streamline the path to regulatory approval, reducing the overall time to market and ensuring broader access to effective treatments. They allow sponsors to build a robust evidence base that meets the rigorous standards of regulatory authorities. This evidence also facilitates discussions with payers and policymakers, ensuring the commercial viability of the therapy. Compassionate use programs, while valuable for individuals, often fail to advance these broader objectives.
In conclusion, Compassionate Use and Expanded Access programs are essential for addressing unmet medical needs, particularly for patients with limited time or options. However, they should complement, not replace, traditional clinical trials. In some regions this complementary nature has been fully integrated in the respective legislation. Their limitations in generating high-quality, reproducible data make them unsuitable as a primary strategy for drug development. Sponsors, regulators, and healthcare providers must collaborate to ensure these programs serve their intended purpose: providing hope and access to those in need without compromising the scientific, ethical, and operational integrity of the broader development process. By focusing on rigorous clinical trials, the industry can ensure equitable access to safe and effective therapies for all eligible patients.
